XML 10 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Cover Page - USD ($)
 12 Months Ended
Dec. 31, 2025
Mar. 31, 2026
Jun. 30, 2025
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2025    
Document Fiscal Year Focus 2025    
Document Fiscal Period Focus FY    
Entity Registrant Name Alaunos Therapeutics, Inc.    
Entity Central Index Key 0001107421    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Trading Symbol TCRT    
Document Transition Report false    
Document Annual Report true    
Security Exchange Name NASDAQ    
Title of 12(b) Security Common Stock    
Entity File Number 001-33038    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 501 E. Las Olas Blvd.,    
Entity Address, Address Line Two Suite 300    
Entity Address, City or Town Fort Lauderdale,    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 33301    
Entity Tax Identification Number 84-1475642    
City Area Code 346    
Local Phone Number 355-4099    
Entity Well-known Seasoned Issuer No    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company false    
Document Financial Statement Error Correction [Flag] false    
ICFR Auditor Attestation Flag false    
Entity Common Stock, Shares Outstanding   2,378,253  
Entity Public Float     $ 9,608,631
Auditor Name Cherry Bekaert LLP    
Auditor Location Tampa, Florida    
Auditor Firm ID 677    
Auditor Opinion [Text Block]

Opinion on the Financial Statements

 

We have audited the accompanying balance sheet of Alaunos Therapeutics, Inc. (the “Company”) as of December 31, 2025, and the related statements of operations, stockholders’ equity, and cash flows the year ended December 31, 2025, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the year ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

The financial statements of the Company as of and for the year ended December 31, 2023, before the retroactive adjustments described in Note 3 with respect to the July 2024 one-for-ten reverse stock split were audited by other auditors whose report, dated April 1, 2024, expressed an unqualified opinion, with an explanatory paragraph expressing substantial doubt regarding the Company’s ability to continue as a going concern, on those statements. We also audited the adjustments described in Note 3 that were applied retroactively to the 2023 financial statements to reflect the July 2024 one-for-ten reverse stock split and the related disclosures included therein. In our opinion, such adjustments and related disclosures are appropriate and have been properly applied. We were not engaged to audit, review, or apply any procedures to the 2023 financial statements of the Company other than with respect to the adjustments and disclosures referred to herein and, accordingly, we do not express an opinion or any other form of assurance on the 2023 financial statements taken as a whole.

    
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Proxy Statement for the Registrant's 2026 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.